Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Interferon Beta-1a and Peginterferon Beta-1a in Healthy Subjects
NCT04183491Phase 1Completed
- Sponsor
- Food and Drug Administration
- Start
- Feb 2020
- Primary completion
- Jan 2021
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of interferon beta-1a and peginterferon beta-1a in multiple sclerosis (MS) (7 arms), sponsored by Food and Drug Administration. Primary endpoints: Area Under Effect Curve for Neopterin and Maximum Change From Baseline for Neopterin. Started Feb 2020; status: completed.
02
Drugs
interferon beta-1apeginterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT04183491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04183491.